Toxins and drug discovery

Research output: Contribution to journalArticle

89 Citations (Scopus)
148 Downloads (Pure)

Abstract

Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalToxicon
Volume92
Early online date29 Oct 2014
DOIs
Publication statusPublished - 15 Dec 2014

Fingerprint

Drug Discovery
Captopril
Venoms
Medicine
Assays
Screening
Industry
Therapeutics

Keywords

  • conus venoms
  • drug development venoms to drugs
  • drug discovery
  • phenotypic screening
  • snake venoms

Cite this

Harvey, Alan L. / Toxins and drug discovery. In: Toxicon. 2014 ; Vol. 92. pp. 193-200.
@article{ba645d009f824a72b9f04f98c6e0e4d7,
title = "Toxins and drug discovery",
abstract = "Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.",
keywords = "conus venoms, drug development venoms to drugs, drug discovery, phenotypic screening, snake venoms",
author = "Harvey, {Alan L.}",
year = "2014",
month = "12",
day = "15",
doi = "10.1016/j.toxicon.2014.10.020",
language = "English",
volume = "92",
pages = "193--200",
journal = "Toxicon",
issn = "0041-0101",

}

Toxins and drug discovery. / Harvey, Alan L.

In: Toxicon, Vol. 92, 15.12.2014, p. 193-200.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Toxins and drug discovery

AU - Harvey, Alan L.

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.

AB - Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.

KW - conus venoms

KW - drug development venoms to drugs

KW - drug discovery

KW - phenotypic screening

KW - snake venoms

UR - http://www.scopus.com/inward/record.url?scp=84910060829&partnerID=8YFLogxK

UR - http://www.sciencedirect.com/science/article/pii/S0041010114003511

U2 - 10.1016/j.toxicon.2014.10.020

DO - 10.1016/j.toxicon.2014.10.020

M3 - Article

AN - SCOPUS:84910060829

VL - 92

SP - 193

EP - 200

JO - Toxicon

JF - Toxicon

SN - 0041-0101

ER -